Last reviewed · How we verify
ART 50
ART 50 is an antiretroviral medication used to treat HIV-1 infection.
ART 50 is an antiretroviral medication used to treat HIV-1 infection. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV-1.
At a glance
| Generic name | ART 50 |
|---|---|
| Sponsor | Laboratoires NEGMA |
| Drug class | Non-nucleoside reverse transcriptase inhibitor |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
ART 50 works by inhibiting the replication of the HIV-1 virus through its action on the viral reverse transcriptase enzyme. This leads to a decrease in the viral load and an increase in the CD4 cell count. ART 50 is often used in combination with other antiretroviral medications to achieve optimal treatment outcomes.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV-1
Common side effects
- Nausea
- Headache
- Fatigue
- Diarrhea
- Abdominal pain
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks (PHASE4)
- Differentiated Service Delivery for Pregnant and Postpartum Women Living With HIV and Their Infants (NA)
- Group Intervention for Interpersonal Skills (NA)
- CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS (EARLY_PHASE1)
- Spironolactone and XPB-1 Integrity in the TFIIH Complex (NA)
- Auditory Stimulation During Sleep to Enhance Long-Term Memory in Amnestic MCI (NA)
- SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |